A Study of LY3945262 in Healthy Participants
A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY3945262 and an Open Label, Randomized, Fixed Sequence, Relative Bioavailability Study of LY3945262 in Healthy Participants
The main purpose of this study is to evaluate how well LY3945262 is tolerated, what side effects may occur, and how much LY3945262 gets into the bloodstream and how long it takes the body to remove it in healthy participants. The study will also compare how LY3945262 gets into the bloodstream when administered in different ways.
This study will last approximately 8 weeks and may include up to 4 visits.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 電話番号:1-317-615-4559
- メール:LillyTrials@Lilly.com
研究連絡先のバックアップ
- 名前:Physicians interested in becoming principal investigators please contact
- メール:clinical_inquiry_hub@lilly.com
研究場所
-
-
California
-
Los Alamitos、California、アメリカ、90720
- Collaborative Neuroscience Network - CNS
-
主任研究者:
- Steven Reynolds
-
コンタクト:
- 電話番号:844-424-9494
-
-
Texas
-
San Antonio、Texas、アメリカ、78232
- ICON Early Phase Services
-
コンタクト:
- 電話番号:210-283-4500
-
主任研究者:
- Chinonye Ogbonnaya-Odor
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiogram (ECG).
- To qualify as Japanese for the purpose of this study, the participant must be first generation Japanese, defined as the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan.
- To qualify as Chinese for the purpose of this study, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participant's biological grandparents must be of exclusive Chinese descent, and must have been born in China.
-
Individuals assigned male at birth (AMAB) and individuals not of childbearing potential (INOCBP) may participate in this trial. Individuals of childbearing potential (IOCBP) are excluded from this trial.
-
Have a body weight of at least 50 kilogram (kg) and body mass index within the range of 18.5 to less than or equal to 35 kilogram per square meter (kg/m²).
Exclusion Criteria:
-
Have a significant history, or current evidence, of any of the following types of disorders that could significantly alter the absorption, metabolism, or elimination of drugs; pose a risk during administration of the investigational product; or interfere with data interpretation:
- cardiovascular
- respiratory, including bronchospasm or bronchial asthma, or chronic obstructive airways disease
- hepatic
- renal
- gastrointestinal
- endocrine, such as diabetes, acromegaly, Cushing syndrome, hyper- or hypothyroidism (Including subclinical hypothyroidism measured using thyroid stimulating hormone), or hyperaldosteronism
- hematological
-
Have a history of hypertension, or a blood pressure (BP) reading that is abnormal for the population
-
Have known or ongoing psychiatric disorders.
-
Have used or intend to use over the counter or herbal supplements (for example, St. John's wort) or prescription medication within 14 days or 5 half-lives, whichever is longer, before initial dosing or during the study. If this situation arises, inclusion of an otherwise suitable participant may be at the discretion of the investigator and sponsor.
-
Regularly use known drugs of abuse and/or show positive findings on drug screening.
-
Are currently enrolled in any other clinical trial involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
-
Have participated, within the past 30 days, in a clinical study involving an investigational product with a short half-life. If the previous investigational product has a long half-life, 3 months or 5 half-lives, whichever is longer, should have passed.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:LY3945262 Part A (SAD)
Single Ascending Doses (SAD) of LY3945262 administered orally |
Administered Orally |
|
プラセボコンパレーター:Placebo Part A (SAD)
Placebo administered orally |
Administered Orally |
|
実験的:LY3945262 Part B (MAD)
Multiple Ascending Doses (MAD) of LY3945262 administered orally. Participants will also receive 2 doses of Midazolam (one before and one with LY3945262) administered orally. |
Administered Orally Administered orally |
|
プラセボコンパレーター:Placebo Part B (MAD)
Placebo administered orally. Participants will also receive 2 doses of Midazolam (one before and one with placebo) administered orally. |
Administered Orally Administered orally |
|
実験的:LY3945262 Part C (Test)
LY3945262 tablet formulation administered orally |
Administered Orally |
|
アクティブコンパレータ:LY3945262 Part C (Reference)
LY3945262 capsule formulation administered orally |
Administered Orally |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
時間枠:Baseline to Study Completion (Up to 8 weeks)
|
Baseline to Study Completion (Up to 8 weeks)
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3945262
時間枠:Baseline to Study Completion (Up to 8 Weeks)
|
Baseline to Study Completion (Up to 8 Weeks)
|
|
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3945262
時間枠:Baseline to Study Completion (Up to 8 weeks)
|
Baseline to Study Completion (Up to 8 weeks)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 27951
- J8C-MC-LBDA (その他の識別子:Eli Lilly and Company)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。